Sanofi current report, Q2 FY2004

Sanofi-Synthelabo Form 6-K Summary

Business Context and Reporting Period

This Form 6-K was filed by Sanofi-Synthelabo on May 26, 2004. The report serves to incorporate by reference two press releases issued on the same date regarding corporate governance and a U.S. securities offering. The registrant files annual reports on Form 20-F.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to disclose non-financial corporate events rather than a financial results announcement.

Material Changes

No material financial changes versus prior periods are disclosed in this document. The filing focuses on the following corporate actions:

  • Announcement of nominees proposed for election as directors at the General Meeting of shareholders.
  • Announcement of an extension of a U.S. offer.

Guidance, Outlook, and Risks

The filing does not contain management commentary on financial guidance, outlook, risks, contingencies, or unusual items. It references a Registration Statement on Form F-4 (No. 333-112314) declared effective on May 13, 2004, into which this report is incorporated.

Investor Verification Checklist

  • Verify the full list of director nominees in the attached press release (Exhibit 99.1).
  • Confirm the specific terms and new deadline of the extended U.S. offer (Exhibit 99.2).
  • Review the related Form F-4 Registration Statement for detailed offering terms.
  • Note that no financial performance data is included in this specific filing.